Staff Profile

Dr Stuart McPherson is a Consultant Hepatologist at the Liver Transplant Unit at the Newcastle upon Tyne Hospitals NHS Foundation Trust and an Honorary Professor at Newcastle University.

Stuart’s major clinical interests include viral hepatitis, steatotic liver disease, cirrhosis and liver transplantation.

Dr McPherson is research active with > 100 publications in viral hepatitis, steatotic liver disease and cirrhosis. He is also PI for multiple commercial clinical trials.

Other roles:

Clinical lead of The Newcastle Liver Unit

Clinical lead for North East and Cumbria Hepatitits C Operational Delivery Network

Deputy Vice President (Hepatology) of British Society of Gastroenterology

Chair for the BSG/BASL NAFLD Special Interest Group

Previous roles:

Senior Secretary of the British Society of Gastroenterology 2019-2021

Secretary of the British Society of Gastroenterology 2017-2019

NICE Clinical Advisor  2018-2021

Hepatology speciality lead for North East and North Cumbria CRN  2012 – 2017

Chair of British Transplantation Society Guideline Development Group for Hepatitis B and E  2016

British Society of Gastroenterology liver committee member 2013 – 2016

Early Detection of Liver disease

I am the CI on the MRC funded SOLID study that aims to evaluate liver fibrosis biomarkers to identify liver disease in the community. In this study we will recruit 3000 patients over 2 years with the aim of developing the most clinically and cost effective pathway to identify patients with significant liver disease in primary care.

Non-alcoholic fatty liver disease (NAFLD)

My current focus for research in fatty liver disease is around risk stratification of patients using non-invasive markers of liver fibrosis. I am a core member of the €34M Newcastle led pan-European LITMUS consortium that is developing biomarkers to stage and monitor disease activity in NAFLD.

I am also committed to improving clinical care delivery and have developed a care bundle that was shown to improve the care of patients with NAFLD. Moreover, I am the lead author on the BASL/BSG Special Interest Group Quality Standards Guideline for the Care of Patients with NAFLD.

Viral Hepatitis

My current research in viral hepatitis is focused around assessing the efficacy of innovative methods of blood borne virus testing and hepatitis C treatment in drug treatment services, community pharmacies and prisons. In addition, I am evaluating novel approaches to the detection and prevention of hepatitis C reinfection following antiviral treatment.

Cirrhosis

I am passionate about improving the care of patients with cirrhosis. I led the development of a care bundle for patients with decompensated cirrhosis, which is now endorsed by the British Society of Gastroenterology (BSG) and widely used across the UK. We have now demonstrated, in a multicentre study that use of the bundle substantially improves care of these patients. We were awarded the Royal College of Physicians Quality Improvement award in 2017. We have now developed are a decompensated cirrhosis discharge bundle that also improves care and has been endorsed by the BSG.

Lead for the 4th year CSIM2 course liver week 2010-2020

SSC supervisor - currently arranged privately

ACE student supervisor

• Articles

  • Allsop C, Mcque K, Roberts M, Jelley R, Murphy S, Richardson C, Coyte A, Taha Y, McPherson S. What is the impact of a Hepatitis C ‘test, trace and treat’ pilot using peer workers?. Journal of Viral Hepatitis 2023, 30(12), 922-925.
  • Sy A, McCabe L, Hudson E, Ansari AM, Pedergnana V, Lin S-K, Santana S, Fiorino M, Ala A, Stone B, Smith M, Nelson M, Barclay ST, McPherson S, Ryder SD, Collier J, Barnes E, Walker AS, Pett SL, Cooke G. Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. PloS one 2023, 18(1), e0280551.
  • McPherson S, Jarvis H, McGonigle J, Bedlington J, Dean J, Hallsworth K, Hanon E, Liddle T, Luvai A, Mansour D, Patel P, Renwick L, Teare D, Tanney C, Anstee Q. Stratification of LIver Disease (SOLID): Protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface. BMJ Open Gastroenterology 2023, 10(1), e001092.
  • Li W, Sheridan D, McPherson S, Alazawi W. National study of NAFLD management identifies variation in delivery of care in the UK between 2019-2022. JHEP Reports 2023, 5(12), 100897.
  • Gallacher J, Taha Y, da Silva Filipe A, Ijaz S, McPherson S. Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection. IDCases 2023, 32, e01741.
  • Johnson A, Shearer J, Thompson C, Jelley R, Aldridge J, Allsop C, Kerry J, Jones D, McCullough F, Miller C, Valappil M, Taha Y, Masson S, Jefferson T, Lawton C, Christensen L, McPherson S. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons. Journal of Viral Hepatitis 2023, 30(12), 914-921.
  • Avery L, Smith H, McPherson S, Hallsworth K. Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE). Pilot and Feasibility Studies 2023, 9, 62.
  • Tingle S, Bramley R, Goodfellow M, Thompson E, McPherson S, White S, Wilson C. Donor Liver Blood Tests and Liver Transplant Outcomes: UK Registry Cohort Study. Transplantation 2023, 107(12), 2533-2544.
  • Hamill V, Gelson W, MacDonald D, Richardson P, Ryder S, Aldersley M, McPherson S, Verma S, Sharma R, Hutchinson S, Benselin J, Barnes E, Guha IN, Irving W, Innes H. Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International 2023, 43(4), 917-927.
  • Malik AK, Varghese C, Pandanaboyana S, Sen G, Robinson S, McPherson S, Dyson J, Manas DM, Masson S, Hammond JS. Risk factors for decompensation and death following umbilical hernia repair in patients with end-stage liver disease. European Journal of Gastroenterology & Hepatology 2022, 34(10), 1060-1066.
  • McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, McCallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterology and Hepatology 2022, 7(8), 755-769.
  • Smethurst K, Gallacher J, Jopson L, Majiyagbe T, Johnson A, Copeman P, Mansour D, McPherson S. Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle. Frontline Gastroenterology 2022, 13(5), 409-415.
  • Askar S, Jelley R, McQue K, Allsop C, McCullough F, Miller C, Taha Y, Masson S, McPherson S. Determining the frequency and characteristics of Hepatitis C reinfections in North East England. Journal of Viral Hepatitis 2022, 29(8), 685-690.
  • Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, Hoare T, Anderson K, Mcneil M, Mcpherson S, Masson S, Dyson J, Donnelly M, Macdougal L, Patel P, Hudson M, Anstee QM, White S, Robinson S, Pandanaboyana S, Walker L, Mccain M, Bury Y, Raman S, Burt A, Parkinson D, Haugk B, Darne A, Wadd N, Asghar S, Mariappan L, Margetts J, Stenberg B, Scott J, Littler P, Manas DM, Reeves HL. COVID-19 and liver cancer: Lost patients and larger tumours. BMJ Open Gastroenterology 2022, 9(1), e000794.
  • Abeysekera KWM, Macpherson I, Glyn-Owen K, McPherson S, Parker R, Harris R, Yeoman A, Rowe IA, Dillon JF. Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. Lancet Gastroenterology and Hepatology 2022, 7(8), 770-780.
  • Crocombe D, Ahmed N, Balakrishnan I, Bordea E, Chau M, China L, Corless L, Danquah V, Dehbi H-M, Dillon JF, Forrest EH, Freemantle N, Gear DP, Hollywood C, Hunter R, Jeyapalan T, Kallis Y, McPherson S, Munteanu I, Portal J, Richardson P, Ryder SD, Virk A, Wright G, O'Brien A. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis—study protocol for an interventional randomised controlled trial. Trials 2022, 23(1), 812.
  • Koo S, Sharp L, Hull M, Rushton S, Neilson LJ, McPherson S, Rees CJ. Uncovering undiagnosed liver disease: Prevalence and opportunity for intervention in a population attending colonoscopy. BMJ Open Gastroenterology 2021, 8(1), e000638.
  • Jarvis H, McPherson S, Anstee QM, Hanratty B. The pathway to better primary care for chronic liver disease. British Journal of General Practice 2021, 71(705), 180-182.
  • Cooke GS, Pett S, McCabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch'Ng C, Stone B, Wiselka M, Forton D, McPherson S, Halford R, Nguyen D, Smith D, Ansari A, Dennis E, Hudson F, Barnes EJ, Walker AS. Strategic treatment optimization for HCV (STOPHCV1): A randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research 2021, 6(93).
  • Gallacher J, McPherson S. Progress towards micro-elimination of hepatitis C in the custodial setting. Journal of Viral Hepatitis 2021, 28(2), 300-301.
  • Neilson LJ, MacDougall L, Lee PS, Hardy T, Beaton D, Chandrapalan S, Ebraheem A, Hussien M, Galbraith S, Looi S, Oxenburgh S, Phaw NA, Taylor W, Haigh L, Hallsworth K, Mansour D, Dyson JK, Masson S, Anstee Q, McPherson S. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterology 2021, 12(7), 578-585.
  • Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, Toyoda H, Irving WL, Agarwal K, Aldersley M, Ala A, Aspinall R, Barnes E, Brown A, Corless L, Cramp M, Forton D, Foster G, Foxton M, Gelson W, Gorard D, Gordon F, Khakoo S, Lawson A, McPherson S, Moreea S, Mutimer D, Prince M, Richardson P, Rosenberg W, Ryder S, Sreedharan A, Sreedharan A, Stone B, Ustianowski A, Verma S, Wiselka M. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 2021, 28(1), 168-176.
  • Sudhindar PD, Wainwright D, Saha S, Howarth R, McCain M, Bury Y, Saha SS, McPherson S, Reeves H, Patel AH, Faulkner GJ, Lunec J, Shukla R. HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway. Cancers 2021, 13(20), 5079.
  • Scragg J, Hallsworth K, Taylor G, Cassidy S, Haigh L, Boyle M, Anstee QM, McPherson S, Avery L. Factors associated with engagement and adherence to a low energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. BMJ Open Gastroenterology 2021, 8(1), e000678.
  • Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Reports 2021, 3(4), 100293.
  • Hallsworth K, McPherson S, Anstee QM, Flynn D, Haigh L, Avery L. Digital Intervention with Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults with Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. Journal of Medical Internet Research 2021, 23(1), e20491.
  • Hallsworth K, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, McPherson S, Campbell M. Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C. BMJ Open Gastroenterology 2021, 8(1), e000591.
  • McPherson S, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, Hallsworth K, Campbell M. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. BMJ Open Gastroenterology 2020, 7(1), e000470.
  • Bhandari R, Morey S, Hamoodi A, Thompson C, Jones D, Hewett M, Hunter E, Taha Y, McPherson S. High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons. Journal of Viral Hepatitis 2020, 27(4), 449-452.
  • Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, Trenell MI, Anstee QM, McPherson S, Hallsworth K. Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with non-alcoholic fatty liver disease. Clinical and Translational Gastroenterology 2020, 11(9), e00231.
  • Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wong VWS, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. Gastroenterology 2020, 158, 1611-1625.
  • Hallsworth K, Dombrowski SU, McPherson S, Anstee QM, Avery L. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. Translational Behavioural Medicine 2019, (ePub ahead of Print).
  • Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Newton JL, Trenell MI. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. Journal of Hepatology 2019, 70(6), 1203-1213.
  • Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports 2019, 1(3), 188-198.
  • Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Advances in Therapy 2019, 36(12), 3458-3470.
  • Simpson H, Manley P, Lawler J, Morey S, Buchanan E, Hewett M, Knowles J, Miller C, McCarron B, Valappil M, McPherson S. Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. Journal of Public Health 2019, 41(4), 700-706.
  • Ankcorn M, Gallacher J, Ijaz S, Taha Y, Harvala H, Maclennan S, Thomson EC, Davis C, Singer JB, da Silva Filipe a, Smollett K, Niebel M, Semple MG, Tedder RC, McPherson S. Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology 2019, 71(2), 434-438.
  • Haigh L, Bremner S, Houghton D, Henderson E, Avery L, Hardy T, Hallsworth K, McPherson S, Anstee QM. Barriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern Europe. Clinical Gastroenterology and Hepatology 2019, 17(7), 1364-1371.e3.
  • Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, McPherson S, Mutimer D, Gelson W. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. Journal of Viral Hepatitis 2018, 26(2), 231-235.
  • Morey S, Hamoodi A, Jones D, Young T, Thompson C, Dhuny J, Buchanan E, Miller C, Hewett M, Valappil M, Hunter E, McPherson S. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. Journal of Viral Hepatitis 2018, 26(1), 101-108.
  • Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette M, Cave M, Hagerty D, Spada A, Jalan R. A Placebo-Controlled, Multicenter, Double-Blind, Phase2 Randomised Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. Journal of Clinical and Experimental Hepatology 2018, 8(3), 224-234.
  • Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Stallmach A, Engelmann C, Trepte C, Capel J, De Gottardi A. Treatment of refractory ascites with an automated low-flowascites pump in patients with cirrhosis. Alimentary Pharmacology and therapeutics 2017, 46(10), 981-991.
  • Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, Henderson E, Tiniakos D, White S, French J, Mann DA, Anstee QM, Mann J. Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 2017, 66(7), 1321-1328.
  • Avery L, Exley C, McPherson S, Trenell MI, Anstee QM, Hallsworth K. Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. Clinical Gastroenterology and Hepatology 2017, 15(12), 1968-1971.
  • Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, McPherson S, Anstee QM, Trenell MI. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2017, 15(1), 96-102.e3.
  • Houghton D, Hallsworth K, Thoma C, Cassidy S, Hardy T, Heaps S, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Trenell MI. Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. Clinical Gastroenterology and Hepatology 2017, 15(10), 1596-1603.e3.
  • Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology 2017, 8(4), 252-259.
  • McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt AD, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. American Journal of Gastroenterology 2017, 112(5), 740-751.
  • McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One 2017, 12(4), e0175717.
  • McPherson S, Dyson JK, Austin A, Hudson M. Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h. Frontline Gastroenterology 2016, 7(1), 16-23.
  • Dyson JK, McPherson S. Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy". Journal of Hepatology 2016, 64(3), 753-754.
  • Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, Aldersley MA, McPherson S. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. Journal of Hepatology 2016, 64(1), 234-238.
  • Dyson JK, Jopson L, Ng S, Lowery M, Harwood J, Waugh S, Valappil M, McPherson S. Improving testing for hepatitis B before treatment with rituximab. European Journal of Gastroenterology & Hepatology 2016, 28(10), 1172-1178.
  • Dyson JK, Rajasekhar P, Wetten A, Hamad AH, Ng S, Paremal S, Baqai MF, Lamb CA, Masson S, Hudson M, Dipper C, Cowlam S, Hussaini H, McPherson S. Implementation of a “care bundle” improves the management of patients admitted to hospital with decompensated cirrhosis. Alimentary Pharmacology and Therapeutics 2016, 44(10), 1030–1038.
  • Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NC, Jamieson D, Reeves HL. Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology 2016, 65(2), 305-313.
  • Darke J, Cresswell T, McPherson S, Hamoodi A. Hepatitis C in a prison in the North East of England: What is the economic impact of the universal offer of testing and emergent medications?. Journal of Public Health 2016, 38(4), e554-e562.
  • McPherson S, Lucey MR, Moriarty KJ. Decompensated alcohol related liver disease: acute management. BMJ 2016, 352, i124.
  • McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology 2015, 62(5), 1148-1155.
  • Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, Allison MED, Alexander GJ, Piguet A-C, Anty R, Donaldson P, Aithal GP, Francque S, VanGaal L, Clement K, Ratziu V, Dufour J-F, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease. Nature Communications 2014, 5, 4309.
  • McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2014, 60(5), 1055-1062.
  • Dyson JK, Hudson M, McPherson S. Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clinical Medicine 2014, 14(5), 551-555.
  • McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R, Hudson M, Bassendine MF. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. Journal of Viral Hepatitis 2013, 20(9), 638-644.
  • McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. European Journal of Gastroenterology & Hepatology 2013, 25(6), 652-658.
  • Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease?. BMJ 2011, 343, d3897.
  • McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59(9), 1265-1269.
  • Van Der Laan L, Hudson M, McPherson S, Zondervan P, Thomas R, Kwekkeboom J, Lindsay A, Burt A, Kazemier G, Tilanus H, Bassendine M, Metselaar H. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplantation Proceedings 2010, 42(10), 4573-4577.
  • McPherson S, Jonsson J, Cowin G, O'Rourke P, Clouston A, Volp A, Horsfall L, Jothimani D, Fawcett J, Galloway G, Benson M, Powell E. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. Journal of Hepatology 2009, 51(2), 389-397.
  • McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. Journal of Hepatology 2008, 49(6), 1046-1054.

• Editorials

  • Hardy T, Mcpherson S. Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. Alimentary Pharmacology & Therapeutics 2018, 47(7), 1035-1036.
  • Gallacher J, McPherson S. Progress towards a simple tool for screening for hepatic steatosis in the general population. Alimentary Pharmacology and Therapeutics 2017, 46(5), 559-560.
  • McPherson S, Dyson JK, Hudson M. Editorial: improving in-hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration and lessons to learn. Authors’ reply. Alimentary Pharmacology and Therapeutics 2017, 45(5), 755-756.
  • Mansour D, McPherson S. Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD. Alimentary Pharmacology and Therapeutics 2017, 45(9), 1269-1270.
  • McPherson S, Anstee QM. Changing Epidemiology of Chronic Liver Disease Among Ethnic Groups in the United States. Hepatology 2016, 64(6), 1843-1846.
  • Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M. Lesson of the Week: Cholestasis secondary to anabolic steroid use in young men. British Medical Journal 2012, 344, e468.

• Letters

  • Scragg J, Charman SJ, van Hees VT, Avery L, Taylor GS, Anstee QM, McPherson S, Cassidy S, Hallsworth K. Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. American Journal of the Medical Sciences 2022, 363(1), 80-83.
  • Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R. Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics 2022, 56(1), 182-183.
  • Cowin G, Jonsson J, McPherson S, Clouston A, Benson M, Powell E, Galloway G. Combined approach for non-invasive measurement of liver pathology by MR. Journal of Hepatology 2009, 51(6), 1083-1084.

• Reviews

  • Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World Journal of Gastroenterology 2022, 28(1), 76-95.
  • Lu L, Koo S, McPherson S, Hull MA, Rees CJ, Sharp L. Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Disease 2022, 24(6), 681-694.
  • McPherson S, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, Tedder R, Andrews PA. Summary of the British Transplantation Society UK Guidelines for Hepatitis e and Solid Organ Transplantation. Transplantation 2018, 102(1), 15-20.
  • Gallacher J, McPherson S. Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. European Medical Journal 2018, 3(2), 108-118.
  • Mansour D, McPherson S. Management of Decompensated Cirrhosis. Clinical Medicine 2018, 18(2), s60-s65.
  • Hardy T, McPherson S. Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. Current Hepatology Reports 2017, 16(4), 298-307.
  • Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Postgraduate Medical Journal 2015, 91(1072), 92-101.
  • Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal 2014, 90(1063), 254-266.
  • Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology 2013, 66(12), 1033-1045.